natgillin/translations-raw huggingface dataset:
Tell your doctor straight away if you notice the following side effects, as he or she may need to stop your treatment: 
Drugi neželeni učinki so lahko: Če opazite katerega od naslednjih neželenih učinkov se pogovorite z zdravnikom ali medicinsko sestro:
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na posebni recept.
Infections and infestations very common 
Bolezni sečil zelo pogosti okvara ledvic
The following factors had no clinical effect on the clearance of siltuximab: gender, age, and ethnicity. 
Spol, starost in etnična pripadnost nimajo kliničnega učinka na očistek siltuksimaba.
(MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) 
Zdravilo SYLVANT je indicirano za zdravljenje odraslih bolnikov z multicentrično Castlemanovo boleznijo (MCD - multicentric Castleman's disease), ki niso okuženi z virusom humane imunske pomanjkljivosti (so HIV negativni) in niso okuženi s humanim herpesvirusom-8 (so HHV-8
Elderly 
VIALA
Do not use if visibly opaque or if foreign particles and/or solution discolouration are present. 
Če vsebina ni prozorna ali je obarvana in/ali če vsebuje tujke, je ne smete uporabiti.
Each vial should be reconstituted with 5.2 mL of single-use water for injections to yield a 20 mg/mL solution. 
Eno vialo je treba rekonstituirati s 5,2 ml vode za injekcije za enkratno uporabo, da nastane raztopina z
In mice dosed subcutaneously with an anti-mouse IL-6 monoclonal antibody, 
Pri miših, ki so jim subkutano dajali monoklonsko protitelo proti mišjemu IL-6, niso opazili vpliva na plodnost niti pri samcih niti pri samicah.
• rash, itchy skin rash (eczema) 
• izpuščaj, srbeč kožni izpuščaj (ekcem)
During or following infusion, treatment should be discontinued in patients who have severe infusion related hypersensitivity reactions (e.g., anaphylaxis). 
Pri bolnikih, ki imajo hudo preobčutljivostno reakcijo na infuzijo (npr. anafilaksijo), je treba odmerjanje zdravila SYLVANT ukiniti med infundiranjem ali po njem.
Talk to your doctor, pharmacist, or nurse before you are given SYLVANT if: 
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila SYLVANT, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro: • če imate trenutno kakšno okužbo - zdravilo SYLVANT lahko zmanjša vaše zaznavanje, da ste okuženi, oziroma obrambno sposobnost v primeru okužbe in lahko pride do poslabšanja okužbe
3 years 
Zaprta viala 3 leta
This summary was last updated in April 2015. 
Povzetek je bil nazadnje posodobljen aprila 2015.
Most of these dogs also received additional treatment. 
Večina teh psov je bila deležna tudi dodatnega zdravljenja.
Other information about Cerenia: 
Druge informacije o zdravilu Cerenia:
The European Commission granted a marketing authorisation valid throughout the European Union, for Cerenia on 29/09/2006. 
Evropska komisija je dovoljenje za promet z zdravilom Cerenia, veljavno po vsej Evropski uniji, izdala 29. septembra 2006.
Cerenia is a medicine that contains the active substance maropitant. 
Cerenia je zdravilo, ki vsebuje zdravilno učinkovino maropitant.
Information on the prescription status of this product can be found on the label/outer package. 
Podatki o predpisovanju tega zdravila so navedeni na nalepki/zunanji ovojnini.
A large number of studies with Cerenia were carried out either in laboratory dogs and cats or in animal patients at veterinary practices in several European countries and in the USA. 
Z zdravilom Cerenia so bile opravljene številne študije, bodisi na laboratorijskih psih in mačkah bodisi na bolnih živalih v veterinarskih ordinacijah v številnih evropskih državah in ZDA.
Other reported side effects were decreased activity levels and tiredness. 
Drugi neželeni učinki, o katerih so poročali, so bili zmanjšana telesna aktivnost in utrujenost.
What benefit has Cerenia shown during the studies? 
Kakšne koristi je zdravilo Cerenia izkazalo v študijah?
It is available as tablets (16, 24, 60 and 160 mg) for dogs, and as a solution for injection (10 mg/ml) under the skin or into a vein for dogs and cats. 
Na voljo je v obliki tablet (16, 24, 60 in 160 mg) za pse in kot raztopina za injiciranje v podkožje ali v žilo (10 mg/ml) za pse in mačke.
Handling Cerenia does not represent a particular risk for people.However, maropitant can produce short lived eye irritation and in the case of accidental eye exposure, the eyes should be flushed with plenty of water and medical attention sought. 
Dajanje zdravila Cerenia ne predstavlja posebnega tveganja za ljudi, vendar lahko maropitant povzroči kratkotrajno draženje oči.V primeru nenamernega izpostavljanja oči zdravilu jih je treba sprati z veliko vode in poiskati zdravniško pomoč.
Only one out of 16 dogs given Cerenia vomited after receiving morphine, whilst 14 out of 15 dogs given placebo vomited, and in this group, nine of the dogs that vomited did so more than once. 
Samo eden od 16 psov, ki so prejeli zdravilo Cerenia, je bruhal, potem ko so mu dali morfin, od 15 psov, ki so prejeli placebo, pa jih je bruhalo 14, pri čemer je v tej skupini devet psov bruhalo več kot enkrat.
The measures of effectiveness were evidence of retching, vomiting, intensity of nausea and improvements in the speed of recovery by for example measuring time to sit up and stand. 
Merila učinkovitosti so bili znaki siljenja na bruhanje, bruhanje, intenzivnost slabosti in hitrejše okrevanje, ki so ga na primer merili s časom, ki so ga psi potrebovali, da so se usedli ali vstali.
Also, the treatment of vomiting should only be together with other supportive measures or other veterinary therapy while addressing the underlying causes of the vomiting. 
Zdravljenje bruhanja je treba poleg tega izvajati samo skupaj z drugimi podpornimi ukrepi ali drugim veterinarskim zdravljenjem, pri čemer se je treba posvetiti izvirnim vzrokom bruhanja.
The benefit-risk balance can be found in the scientific discussion module of this EPAR. 
Razmerje med koristmi in tveganji je na voljo v modulu znanstvene razprave tega evropskega javnega poročila o oceni zdravila (EPAR).
Cerenia was generally well tolerated. 
Zdravilo Cerenia so živali na splošno dobro prenašale.
Why has Cerenia been approved? 
Zakaj je bilo zdravilo Cerenia odobreno?
What is the risk associated with Cerenia? 
Kakšna tveganja so povezana z uporabo zdravila Cerenia?
Since maropitant could affect heart activity, Cerenia should be used with caution in animals with certain heart conditions. 
Ker bi maropitant lahko vplival na delovanje srca, je treba pri živalih, ki imajo nekatera srčna obolenja, zdravilo uporabljati previdno.
The active substance in Cerenia, maropitant, is broken down in the liver and therefore it is recommended to be used with caution in animals with liver disease. 
Zdravilna učinkovina v zdravilu Cerenia, maropitant, se razgrajuje v jetrih, zato je priporočljivo, da se pri živalih z obolenji jeter uporablja previdno.
Since this was mainly observed in dogs with an empty stomach, it is recommended to feed a light meal or snack a while before the tablets are given. 
Ker so ta učinek opazili predvsem pri psih, ki so tableto dobili na prazen želodec, je priporočljivo, da živali pred prejetjem tablete zaužijejo lahek obrok ali prigrizek.
A very common side effect in cats was evidence of pain from injection under the skin and this may be reduced by injection of the product at refrigerated temperature. 
Zelo pogost neželeni učinek pri mačkah so bile bolečine med injiciranjem v podkožje, kar je mogoče zmanjšati z injiciranjem ohlajenega zdravila.
the animal owner can administer the tablets to the dog. 
Za nadaljevanje zdravljenja lahko lastnik psu daje tablete.
For dogs, the treatment of vomiting should be started with the injection, since vomiting animals might throw the intact tablet up again. 
Zdravljenje bruhanja pri psih je treba začeti z injekcijo, ker bi psi, ki bruhajo, utegnili ponovno izbruhati celo tableto.
The CVMP concluded that the benefits of Cerenia exceed its risks and recommended that Cerenia be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Cerenia večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
In the study looking at the effect of Cerenia before and after surgery, Cerenia was effective at preventing vomiting asociated with the use of morphine. 
V študiji, v kateri so proučevali učinek zdravila Cerenia pred kirurškim posegom in po njem, je bilo zdravilo učinkovito pri preprečevanju bruhanja, povezanega z uporabo morfina.
The bioequivalence studies showed that giving the injection under the skin produced the same levels of maropitant in the body as giving the injection into a vein. 
Študije biološke enakovrednosti so pokazale, da je z injiciranjem v podkožje raven maropitanta v telesu enaka kot z injiciranjem v veno.
A common side effect of the tablets when used at a high dose of 8 mg/kg in dogs (for motion sickness) was vomiting before the car journey started. 
Pogost neželeni učinek tablet, kadar so se uporabljale v visokem odmerku 8 mg/kg pri psih (za preprečevanje slabosti zaradi vožnje), je bilo bruhanje pred začetkom vožnje z avtomobilom.
In case of accidental ingestion or self-injection medical advice should be sought immediately and the package leaflet or the label shown to the physician. 
V primeru nenamernega zaužitja ali samoinjiciranja zdravila se je treba nemudoma posvetovati z zdravnikom in mu pokazati navodilo za uporabo zdravila ali nalepko.
Dogs received either Cerenia soluton for injection or placebo 45 minutes before the administration of morphine for sedation and pain relief prior to anaesthesia . 
Psi so prejeli bodisi zdravilo Cerenia v obliki raztopine za injiciranje bodisi placebo 45 minut preden so prejeli morfin za sedacijo in lajšanje bolečin pred anestezijo.
In dogs the tablets can be used to prevent vomiting due to motion sickness. 
Pri psih se lahko tablete uporabljajo za preprečevanje bruhanja zaradi potovalne slabosti.
What is Cerenia used for? 
Za kaj se zdravilo Cerenia uporablja?
Since Cerenia has not been studied in very young dogs or cats, or in pregnant or lactating bitches or queens, use of Cerenia in these animals should be discussed with your veterinarian. 
Ker zdravila niso proučevali pri zelo mladih psih ali mačkah niti pri brejih oziroma doječih psicah in mačkah, se je treba o njegovi uporabi v teh primerih posvetovati z veterinarjem.
In cats, treatment of vomiting is with the injection only. 
Zdravljenje bruhanja pri mačkah je mogoče samo z injekcijo.
In cats the solution for injection is used to prevent vomiting and to reduce nausea, but is not suitable for motion (travel) sickness. 
Pri mačkah se raztopina za injiciranje uporablja za preprečevanje bruhanja in lajšanje slabosti, ni pa primerna za potovalno slabost.
In order to study the effect of Cerenia in motion sickness, dogs prone to vomiting when travelling were taken on car journeys lasting several hours for up to two consecutive days. 
Da bi proučili učinek zdravila Cerenia pri slabosti zaradi vožnje, so pse, ki so bili nagnjeni k bruhanju med potovanji, peljali na večurno vožnjo z avtomobilom največ dva dneva zapored.
Cerenia solution for injection is used in dogs both to prevent nausea and vomiting before and after an operation and to improve recovery from general anaesthesia after use of morphine. 
Pri psih se raztopina za injiciranje uporablja za preprečevanje slabosti in bruhanja pred operacijo in po njej ter za hitrejše okrevanje po splošni anesteziji, pri kateri je bil uporabljen morfin.
Bioequivalence studies were conducted in both dogs and cats to compare giving the injection under the skin with injection into a vein. 
Pri psih in mačkah so bile izvedene študije biološke enakovrednosti, da bi primerjali injiciranje v podkožje z injiciranjem v veno.
A further study involving dogs looked at the prevention of nausea and vomiting before and after surgery. 
V dodatni študiji pri psih, so proučevali preprečevanje slabosti in bruhanja pred operacijo in po njej.
For the treatment of vomiting, the effect of Cerenia compared with placebo was examined in sick cats that were vomiting for various reasons. 
Za zdravljenje bruhanja so učinke zdravila v primerjavi s placebom proučevali na bolnih mačkah, ki so bruhale iz različnih razlogov.
What is Cerenia? 
Kaj je zdravilo Cerenia?
For the prevention of vomiting, Cerenia was studied in cats which received either Cerenia or placebo before another substance known to trigger vomiting was given to them. 
Za preprečevanje bruhanja so zdravilo Cerenia proučevali pri mačkah, ki so prejele bodisi zdravilo Cerenia bodisi placebo, preden so jim dali kakšno drugo snov, za katero je znano, da povzroča bruhanje.
How has Cerenia been studied? 
Kako je bilo zdravilo Cerenia raziskano?
As injection under the skin causes pain in cats, the animal will need to be restrained when treated. 
Ker so za mačke injekcije v podkožje boleče, jih je treba med zdravljenjem imobilizirati.
For the prevention of vomiting, Cerenia was studied in dogs which received either Cerenia or a placebo (a dummy tablet or injection) before another substance known to trigger vomiting (such as certain cancer medicines) was given to them. 
Za preprečevanje bruhanja so zdravilo Cerenia proučevali pri psih, ki so prejeli bodisi zdravilo Cerenia bodisi placebo (tableto ali injekcijo brez zdravilne učinkovine), preden so jim dali kakšno drugo snov, za katero je znano, da povzroča bruhanje (na primer nekatera zdravila proti raku).
How does Cerenia work? 
Kako zdravilo Cerenia deluje?
For the treatment of vomiting, the effect of Cerenia (or a placebo) was examined in sick dogs that were vomiting for various reasons, for example because of a gastrointestinal infection. 
Učinek zdravila Cerenia (ali placeba) za zdravljenje bruhanja so proučevali pri bolnih psih, ki so bruhali iz različnih razlogov, na primer zaradi okužbe prebavil.
Dogs were treated with either 1 mg/kg (injection given under the skin) or 2 mg/kg (tablet) once daily up to five days. 
Pse so zdravili z odmerki 1 mg/kg (z injekcijami v podkožje) ali 2 mg/kg (s tabletami) enkrat dnevno za največ pet dni.
Cerenia is used to prevent (tablets and solution for injection) and treat (solution for injecton) nausea caused by chemotherapy in dogs. 
Zdravilo Cerenia se uporablja za preprečevanje (s tabletami in raztopino) ali zdravljenje slabosti (z raztopino) zaradi kemoterapije pri psih.
Cats were treated with 1 mg/kg (injection given under the skin) once daily up to five days. 
Mačkam so dajali zdravilo v odmerku 1 mg/kg (z injekcijo) enkrat dnevno do pet dni.
Cerenia tablets are given to dogs at a dose of 8 mg maropitant per kg bodyweight once daily to prevent vomiting due to motion sickness for a maximum of two consecutive days. 
Tablete zdravila Cerenia se psom dajejo enkrat na dan za največ dva dni zapored v odmerku 8 mg maropitanta na kg telesne mase za preprečevanje bruhanja zaradi vožnje.
Cerenia solution for injection is given to dogs and cats once daily under the skin or into a vein (1 mg per kg bodyweight) for up to five days. 
Zdravilo Cerenia se v obliki raztopine psom in mačkam injicira v podkožje enkrat na dan (1 ml na kg telesne mase) za največ pet dni.
The results of the studies showed that Cerenia was more effective than placebo: less vomiting was seen in dogs and cats that received the medicine than in animals that received placebo, both in the treatment or in the prevention of vomiting. 
Pri psih in mačkah, ki so prejeli zdravilo, je bilo opaziti manj pogosto bruhanje kot pri tistih, ki so prejeli placebo, in sicer tako pri zdravljenju kot pri preprečevanju bruhanja.
The animals received either Cerenia tablets at a dose of 8 mg/kg bodyweight or a placebo for up to two consecutive days. 
Psi so največ dva dneva zapored prejemali tablete zdravila Cerenia v odmerku 8 mg/kg telesne mase ali placebo.
Cerenia is used to treat vomiting in dogs and cats (solution for injection) or to prevent vomiting in dogs (tablets), in combination with other supportive measures. 
Zdravilo Cerenia se, skupaj z drugimi podpornimi ukrepi, uporablja za zdravljenje bruhanja pri psih in mačkah (z raztopino za injiciranje) ali preprečevanje bruhanja pri psih (s tabletami).
Cerenia tablets are given to dogs at a dose of 2 mg maropitant per kg bodyweight once daily to prevent or treat vomiting for up to 14 days. 
Tablete zdravila Cerenia se psom dajejo za preprečevanje ali zdravljenje bruhanja enkrat na dan v odmerku 2 mg maropitanta na kg telesne mase za največ 14 dni.
Cerenia blocks neurokinin-1 (NK1) receptors, which are found on the surface of certain cells in the part of the brain that controls nausea and vomitingand are activated by the attachment of a chemical in the body called ‘substance P'. 
Ti so prisotni na površini nekaterih celic v delu možganov, ki nadzoruje slabost in bruhanje, in se aktivirajo, ko se nanje veže kemična snov v telesu, imenovana snov P. Zdravilo Cerenia preprečuje, da bi se snov P vezala na receptorje, in s tem onemogoči njihovo aktiviranje ter ublaži slabost in bruhanje.
Further information on Dectova can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/dectova. 
Nadaljnje informacije o zdravilu Dectova so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/dectova.
The recommended dose for adults is 600 mg twice daily for 5 to 10 days while for children the dose is adjusted based on weight. 
Priporočeni odmerek pri odraslih je 600 mg dvakrat na dan od 5 do 10 dni, medtem ko se pri otrocih odmerek prilagodi glede na telesno maso.
Treatment is started as soon as possible and usually within 6 days after symptoms start. 
Zdravljenje je treba začeti čim prej in običajno v šestih dneh po pojavu simptomov gripe.
Complicated influenza is a severe flu infection that requires hospitalisation of the patient. 
Zapletena influenca je huda okužba z gripo, pri kateri je potrebna hospitalizacija bolnika.
The European Medicines Agency therefore decided that Dectova's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Dectova večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Dectova? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Dectova?
The main measure of effectiveness was how long it took for patients to leave hospital or for 4 out of the following 5 flu symptoms to resolve: fever, decreased levels of oxygen in the blood, raised breathing rate, raised heart rate and abnormal blood pressure. 
Glavno merilo učinkovitosti je bilo, kako dolgo je trajalo, da so bolniki zapustili bolnišnico, ali so izzveneli štirje od naslednjih petih bolezenskih simptomov gripe: zvišana telesna temperatura, nižje ravni kisika v krvi, povečana hitrost dihanja, povečan srčni utrip in nenormalni krvni tlak.
The medicine is used when the virus is resistant to other flu treatments or when other antiviral treatments, including inhaled zanamivir are not suitable for the patient. 
Zdravilo se uporablja, kadar je virus odporen proti drugim zdravilom proti gripi ali kadar druga protivirusna zdravila, vključno z zanamivirjem za inhaliranje, niso primerna za bolnika.
When the neuraminidases are blocked, the virus cannot spread. 
Ko so nevraminidaze zavrte, se virus ne more več širiti.
Dectova is an antiviral medicine used to treat complicated and potentially life-threatening influenza (flu) caused by either the influenza A or B virus in adults and children from 6 months of age. 
Dectova je protivirusno zdravilo ki se uporablja za zdravljenje zapletene in potencialno življenjsko ogrožajoče influence (gripe), ki jo povzročata virus A ali B pri odraslih in otrocih, starejših od šest mesecev.
Further evidence on benefits of Dectova comes from supporting clinical studies and other laboratory studies. 
Dodatni dokazi o koristih zdravila Dectova prihajajo iz podpornih kliničnih študij in drugih laboratorijskih študij.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dectova have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Dectova upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Evidence from laboratory and other clinical studies also supported the effectiveness of Dectova. 
Dokazi iz laboratorijskih in drugih kliničnih študij prav tako podpirajo učinkovitost zdravila Dectova.
Since Dectova has been authorised under exceptional circumstances, the company that markets the medicine will conduct two observational studies in patients with complicated influenza to obtain further data on the effectiveness. 
Ker je zdravilo Dectova pridobilo dovoljenje za promet v izjemnih okoliščinah, bo podjetje, ki ga trži, izvedlo dve opazovalni študiji pri bolnikih z zapletenim potekom gripe, da bo pridobilo dodatne podatke o učinkovitosti zdravila.
Side effects reported with Dectova are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Dectova, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
However, because uncertainties remain about the size of the effect of Tamiflu (and by extension the size of Dectova's effect), Dectova has been authorised under ‘exceptional circumstances'. 
Ker pa še vedno obstajajo negotovosti glede obsega učinka zdravila Tamiflu (in s podaljšanjem obsega učinka zdravila Dectova, je zdravilo Dectova pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
As for all medicines, data on the use of Dectova are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Dectova stalno spremljajo.
An overview of Dectova and why it is authorised in the EU 
Pregled zdravila Dectova in zakaj je odobreno v EU
Other information about Dectova 
Druge informacije o zdravilu Dectova
Although Tamiflu was used as the comparator, there is some uncertainty about how effective this medicine is in complicated influenza as it has not been compared with placebo (a dummy treatment) in hospitalised influenza patients. 
Čeprav je bilo zdravilo Tamiflu uporabljeno kot primerjalno zdravilo, je nekaj negotovosti glede tega, kako učinkovito je to zdravilo pri zapletenem poteku gripe, saj ga niso primerjali s placebom (zdravilom brez učinkovine) pri hospitaliziranih bolnikih z gripo.
Dectova is expected to be effective against some flu strains that do not respond to other flu treatments. 
Zdravilo Dectova naj bi bilo učinkovito proti nekaterim sevom gripe, ki se ne odzivajo na druga zdravljenja proti gripi.
Lower doses are given to adults and children with reduced kidney function. 
Odrasli in otroci z okvaro delovanja ledvic prejmejo nižje odmerke.
For more information about using Dectova, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Dectova glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The active substance in Dectova, zanamivir, prevents the flu virus from spreading by blocking some of the enzymes on the surface of the virus called neuraminidases. 
Učinkovina v zdravilu Dectova, zanamivir, preprečuje širjenje virusa gripe tako, da zavira dejavnost encimov na površini virusa, imenovanih nevraminidaze.
The most common side effects with Dectova (which may affect up to 1 in 10 people) are diarrhoea, raised levels of transaminases (liver enzymes), liver injury and rash. 
Najpogostejši neželeni učinki zdravila Dectova (ki lahko prizadenejo največ 1 osebo od 10) so driska, povišane ravni transaminaz (jetrnih encimov), okvara jeter in izpuščaj.
It took around 5.1 days for symptoms to resolve or patients to leave the hospital with Dectova compared with 5.6 days with Tamiflu. 
Pri jemanju zdravila Dectova so simptomi izzveneli oziroma so bolniki lahko zapustili bolnišnico v približno 5,1 dnevu, v primerjavi s 5,6 dneva pri jemanju zdravila Tamiflu.